Results 161 to 170 of about 63,359 (335)
Metabolic reprogramming in mutant IDH1 glioma cells.
PLoS ONE, 2015 BackgroundMutations in isocitrate dehydrogenase (IDH) 1 have been reported in over 70% of low-grade gliomas and secondary glioblastomas. IDH1 is the enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate while mutant IDH1 ...
Jose L Izquierdo-Garcia +6 more
doaj +1 more source
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors [PDF]
, 2009 David Capper +11 more
openalex +1 more source
Integration of omics data in the diagnosis and therapy of glioblastoma
Brain Pathology, EarlyView.Integration of omics data in the diagnosis and therapy of glioblastoma. Abstract Since the 2016 update of the WHO Classification of Tumors of the Central Nervous System, omics data have been officially integrated into the diagnostic process for glioblastoma, the most prevalent and aggressive primary malignant brain tumor in adults.
Constantin Möller +3 more
wiley +1 more source
Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. [PDF]
, 2018 Adult diffuse gliomas are a diverse group of brain neoplasms that inflict a high emotional toll on patients and their families. The Cancer Genome Atlas and similar projects have provided a comprehensive understanding of the somatic alterations and ...
GLASS Consortium
core
GFAP, Ki67 and IDH1: perhaps the golden triad of glioma immunohistochemistry [PDF]
, 2009 Werner Paulus
openalex +1 more source
Cancer & Metabolism, 2018 Background There is considerable interest in defining the metabolic abnormalities of IDH mutant tumors to exploit for therapy. While most studies have attempted to discern function by using cell lines transduced with exogenous IDH mutant enzyme, in this ...
Matthew Garrett +19 more
doaj +1 more source
European Journal of Haematology, EarlyView.ABSTRACT The treatment of elderly, nonfit acute myeloid leukemia (AML)/MDS patients with relapsed/refractory (R/R) disease remains challenging. As histone demethylase LSD1 (KDM1A) is a rational therapeutic target in AML, we conducted a phase I trial (“rolling‐six design”) with the LSD1 inhibitor tranylcypromine (TCP, dose levels [DL] 20, 40, 60, 80 mg ...
Michael Kruszewski +22 more
wiley +1 more source
The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
Acta Pharmaceutica Sinica B, 2023 Reprogramming of energy metabolism is one of the basic characteristics of cancer and has been proved to be an important cancer treatment strategy. Isocitrate dehydrogenases (IDHs) are a class of key proteins in energy metabolism, including IDH1, IDH2 ...
Yang Liu +7 more
doaj
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis [PDF]
, 2010 Felicitas Thol +13 more
openalex +1 more source
Mutant IDH1 Promotes Glioma Formation In Vivo
Cell Reports, 2018 Isocitrate dehydrogenase 1 (IDH1) is the most commonly mutated gene in grade II-III glioma and secondary glioblastoma (GBM). A causal role for IDH1R132H in gliomagenesis has been proposed, but functional validation in vivo has not been demonstrated.
Gemma L. Robinson +24 more
openaire +4 more sources